Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01126268 · ClinicalTrials.gov registry record · Phase 4
Twice Daily Altabax Application for the Treatment of Uncomplicated Soft Tissue Infection
A Phase 4 study of Impetigo and Folliculitis, sponsored by The University of Texas Health Science Center, Houston.
- Completed
- Registry status
- Phase 4
- Development phase
- 38
- Enrollment target
- 1
- Study location
NCT01126268 is a Phase 4 study of Impetigo and Folliculitis that has completed, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 38 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01126268, a Phase 4 study of Impetigo and Folliculitis, has completed, sponsored by The University of Texas Health Science Center, Houston.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 38 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to document the clinical and bacteriological efficacy of retapamulin in the treatment of subjects with bacterial infections, including impetigo, folliculitis, and minor soft tissue infections including secondarily infected eczema presumed to be caused by methicillin resistant Staph aureus. Male and female patients ages 9 months to 98 years will be recruited from a university based dermatology clinic. Upon enrollment, wound cultures will be collected, and then subjects will apply topical retapamulin twice daily for five days. The primary endpoint will be resolution of methicillin-resistant Staphylococcus aureus (MRSA) infection based on clinical presentation and physical exam, as well as bacteriological efficacy based on culture results. It is anticipated that approximately 75 patients will be enrolled, with expectation that approximately 50 of these patients will have MRSA infections.
Conditions Studied
Interventions
- DRUG Retapamulin (Altabax)
Study Locations (1)
Texas
- Houston Medical Center Building - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2010-04 |
| Est. Completion | 2012-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01126268
The ClinicalTrials.gov registry entry for NCT01126268 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center, Houston, which has 732 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Impetigo appearing as the primary indexed condition, and to 1 intervention - of which Retapamulin (Altabax) is the first listed.
NCT01126268 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT01126268 about?
NCT01126268 is a clinical study titled "Twice Daily Altabax Application for the Treatment of Uncomplicated Soft Tissue Infection". The purpose of this study is to document the clinical and bacteriological efficacy of retapamulin in the treatment of subjects with bacterial infections, including impetigo, folliculitis, and minor soft tissue infections including secondarily infected eczema presumed to be caused by methicillin resi...
What is the current status of trial NCT01126268?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 38 participants. The study started on 2010-04. Estimated completion is 2012-11.
What conditions does trial NCT01126268 study?
This clinical trial studies the following conditions: Impetigo, Folliculitis, Secondarily Infected Eczema, Minor Soft Tissue Infections.
What interventions are being tested in trial NCT01126268?
The interventions under investigation include: Retapamulin (Altabax) (DRUG).
Who is sponsoring clinical trial NCT01126268?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01126268 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Impetigo
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.